associate professor lili zhu-全讯国际

contact information

• office:room 231, researching building 18

• email:

• office phone: 86 21 6425 3379

• office fax: 86 21 6425 3379

working experience and education background

• 2003.09～2008.07 ph.d.biochemistry and molecular biology, fujian institute of research on the structure of matter, chinese academy of sciences

• 2008.08～2011.07 postdoc.university of luebeck, germany

• 2011.08～present associate professor. east china university of science&technology, shanghai, p. r. china

research interests

• drug screening

• drug mechanism

• crystal structure and function studies of disease related protein

• innovative drug design based on structural biology

publication

1. wanqi wang¹, yanyan diao¹, wenjie li¹, yating luo, tingyuan yang, yuyu zhao, tiantian qi, fangling xu, xiangyu ma, huan ge, yingfan liang, zhenjiang zhao, xin liang, rui wang, lili zhu^⁎, honglin li^⁎, yufang xu^⁎. design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of janus kinase 2. bioorg med chem lett. 2019;29(12):1507-1513.

2. fanxun zeng, lina quan, guantian yang, tiantian qi, letian zhang, shiliang li, honglin li, lili zhu*, xiaoyong xu*. structural optimization and structure–activity relationship of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase. molecules, 2019. 24(15) : 2780.

3. yanling wang, huan ge, disha wang, huan he, lu li, yanyan diao, zihao shen, lili zhu, shiliang li, zhenjiang zhao*, honglin li*. design and synthesis of a series of novel macrocycle janus kinase 2 inhibitors. chin. j. chem., 2019. doi: 10.1002/cjoc.201900316

4. qiannan li, tao zhang, shiliang li, linjiang tong, junyu li, zhicheng su, fang feng, deheng sun, yi tong, xiawang, zhenjiang zhao, lili zhu, jian ding, honglin li, hua xie, yufang xu. discovery of potent and non-covalent reversible egfr kinase inhibitors of egfr l858r/t790m/c797s. acs med. chem. lett., 2019. 10(6) : 869-873

5. shiliang li, chun qin, shichao cui, hongling xu, fangshu wu, jiawei wang, mingbo su, xiaoyu fang, dan li, qian jiao, ming zhang, chunmei xia, lili zhu, rui wang, jia li, hualiang jiang, zhenjiang zhao*, jingya li*, honglin li*. discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes. j med chem. 2019;62(5):2348-2361.

6. yi tong¹, qian jiao¹, yuanru liu, jiankun lv, rui wang*, lili zhu*. maprotiline prevents monocrotaline-induced pulmonary arterial hypertension in rats. front pharmacol. 2018;9:1032.

7. , , , , , *, *, *.synthesis, design, and structure–activity relationship of the pyrimidone derivatives as novel selective inhibitors of plasmodium falciparum dihydroorotate dehydrogenase. molecules. 2018, 23(6), 1254.

8. fang bai¹, kangdong liu¹, huiliang li¹, jiawei wang, junsheng zhu, pei hao, lili zhu, shoude zhang, lei shan, weiya ma, ann m. bode, weidong zhang*, honglin li* and zigang dong*. veratramine modulates ap-1-dependent gene transcription by directly binding to programmable dna. nucleic acids res. 2018; 46(2): 546–557.

9. yongjia hao, jiankun lyu, rong qu, yi tong, deheng sun, fang feng, linjiang tong, tingyuan yang, zhenjiang zhao, lili zhu, jian ding, yufang xu*, hua xie*, honglin li*. design, synthesis, and biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1h,3h)-diones as potent and selective epidermal growth factor receptor (egfr) inhibitors against l858r/t790m resistance mutation. j med chem. 2018;61(13):5609-5622.

10. fanxun zeng, tiantian qi, chunyan li, tingfang li, honglin li, shiliang li,* lili zhu*, xiaoyong xu. synthesis, structure–activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase. med. chem. commun.,2017, 8, 1297.

11. fangshu wu,junsheng zhu,honglin li*, lili zhu*. structural analysis of recombinant human ubiquitin-conjugating enzyme ubch5c. acta pharm sin b. 2017;7(3):390-394.

12. guozhen wu¹, lili zhu¹, xing yuan, hao chen, rui xiong, shoude zhang, hao cheng, yunheng shen, huazhang an, tiejun li, honglin li, weidong zhang, britanin ameliorates cerebral ischemia-reperfusion injury by inducing the nrf2 protective pathway. antioxid redox signal. 2017;27(11):754-768.

13. xiuqin hu, disha wang, yi tong, linjiang tong, xia wang,lili zhu, hua xie, shiliang li , you yang, yufang xu. design, synthesis, and evaluation of ribose-modified anilinopyrimidine derivatives as egfr tyrosine kinase inhibitors. front chem. 2017, 15;5:101.

14. qiao li, lina quan，jiankun lyu，zenghui he，xia wang，jiajia meng，zhenjiang zhao，lili zhu*，xiaofeng liu *，honglin li *. discovery of peptide inhibitors targeting human programmed death 1(pd-1) receptor. oncotarget，2016;7(40)：64967~64976.

15. wenlin song，shiliang li，yi tong，jiawei wang，lina quan，zhuo chen，zhenjiang zhao，yufang xu，lili zhu*，xuhong qian *，honglin li*. structure-based design of potent human dihydroorotate  dehydrogenase inhibitors as anticancer agents. medchemcom，2016.01.01，7(7)：1441~1448.

16. jiawei wang, yanyan diao, junsheng zhu, shiliang li, zhenjiang zhao, honglin li *, lili zhu *. biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase. medchemcomm,  2016, 7(5):853-858.

17. yongjia hao, xia wang, tao zhang, deheng sun,yi tong,yuqiong xu,haiyang chen,linjiang tong,lili zhu,zhenjiang zhao,zhuo chen,jian ding,hua xie,yufang xu,honglin li, discovery and structural optimization of n5-substituted 6,7-dioxo- 6,7-dihydropteridines as potent and selective epidermal growth factor receptor (egfr) inhibitors against l858r/t790m resistance mutation. j. med. chem. 2016, 11;59(15):7111-24.

18. shiliang li, hongling xu, shichao cui,fangshu wu, youli zhang,mingbo su,yinghui gong,shaobing qiu,qian jiao,chun qin,jiwei shan,ming zhang,jiawei wang,qiao yin, minghao xu,xiaofeng liu,rui wang,lili zhu,jia li,yufang xu,hualiang jiang, zhenjiang zhao,jingya li,and honglin li. discovery and rational design of natural-product-derived 2-phenyl-3,4-dihydro-2h-benzo[f]chromen-3-amine analogs as novel and potent dipeptidyl peptidase 4 (dpp-4) inhibitors for the treatment of type 2 diabetes.j. med. chem. 2016, 28;59(14):6772-90.

19. junsheng zhu, le han, yanyan diao, xiaoli ren, minghao xu, liuxin xu, shiliang li, qiang li , dong dong, jin huang, xiaofeng liu, zhenjiang zhao, rui wang, lili zhu^*, yufang xu, xuhong qian ^*, and honglin li*.design, synthesis, x-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase. j. med. chem. 2015, 58（3）, 1123-1139.

20. shiliang li¹，guoqin luan¹，xiaoli ren¹，wenlin song，liuxin xu，minghao xu，junsheng zhu，dong dong，yanyan diao，xiaofeng liu，lili zhu，rui wang，zhenjiang zhao，yufang xu，honglin li^(*)，rational design of benzylidenehydrazinyl-substituted thiazole derivatives as potent inhibitors of human dihydroorotate dehydrogenase with in vivo anti-arthritic activity. sci rep. 2015; 5:14836.

21. liyan wang, shoude zhang, junsheng zhu, lili zhu, xiaofeng liu, lei shan, jin huang*, weidong zhang*, honglin li*. identification of diverse natural products as falcipain-2 inhibitors through structure-based virtual screening. bioorg. med. chem. lett. 2014. 24(5): 1261–1264.

22. minghao xu, junsheng zhu, yanyan diao, hongchang zhou, xiaoli ren, deheng sun, jin huang, dongmei han, zhenjiang zhao, lili zhu*, yufang xu*, and honglin li*. novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives. j. med. chem., 2013. 56 (20): 7911–7924

23. yuwei song, huangtao jin, xiaofeng liu, lili zhu*, jin huang*, honglin li*. discovery of non-peptide inhibitors of plasmepsin ii by structure-based virtual screening. bioorg. med. chem. lett., 2013. 23(7) : 2078-2082

24. kunqiang cui¹, weiqiang lu¹, lili zhu¹, xu shen, jin huang. caffeic acid phenethyl ester (cape), an active component of propolis, inhibits helicobacter pulori peptide deformylase activity. biochem. biophys. res. commun., 2013. 435(2):289-294.

25. liyan wang, chunmei yang, weiqiang lu, li liu, rui gao, sha liao, lili zhu, zhenjiang zhao, yufang xu, honglin li*, jin huang, weiping zhu. discovery of new potent inhibitors for carbonic anhydrase ix by structure-based virtual screening. bioorg. med. chem. lett.., 2013. 23 : 3496-3499

26. xiaojuan yu, xue zhao, lili zhu, chuanxin zou, xiaofeng liu, zhenjiang zhao, jin huang* and honglin li*. discovery of novel inhibitors for human farnesyltransferase (hftase) via structure-based virtual screening. med. chem. commun., 2013. 4: 962-971

27. xianwen cao, jing jiang, shoude zhang,lili zhu, juan zou, yanyan diao, weilie xiao, lei shan, handong sun, weidong zhang*, jin huang*, honglin li*. discovery of natural estrogen receptor modulators with structure-based virtual screening. bioorg. med. chem. lett., 2013. 23: 3329-3333

28. lili zhu, shyla george, marco f.schmidt, samer i al-gharabli, jorg rademann, rolf hilgenfeld. peptide aldehyde inhibitors challenge the substrate specificity of the sars-coronavirus main protease. antivir res. 2011, 92 (2)，204-216.

29. lili zhu, cai yuan, zhuo chen, wanyu wang, mingdong huang. expression, purification and characterization of recombinant jerdonitin, a p-ii class snake venom metalloproteinase comprising metalloproteinase and disintegrin domains. toxicon, 2010, 55, 375-380.

30. lili zhu, feng yang, liqing chen, edward j.meehan, mingdong huang. a new drug binding subsite on human serum albumin and drug-drug interaction studied by x-ray crystallography. j struct biol.2008, 162, 40-49.